New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 16, 2020 - The FDA approved Pfizer’s Mylotarg (gemtuzumab ozogamicin), for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older.
Download PDF
Return to publications
